Co-amoxiclav
Phase 3Small molecule
Co-amoxiclav is one of 11 small molecule programs targeting Complication. It is currently in Phase 3.
2
Indications
9
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Antibiotic
#DrugCompanyPhaseTrials
1Acanya
PfizerApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Levaquin
WWim Janssens
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Cefzil
CCordenpharma
Approved
Amoxicillin-Clavulanate
IIterum Therapeutics, International Limited
Phase 3
Co-amoxiclav
IImperial College London
Phase 3
Keflex
Eli LillyPreclinical
Ancef
BBaxter Healthcare Corporation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Wound Infection2 trials
Antibiotic2 trials
Routine Antibiotic vs. Directed Antibiotic Treatment in Snake Bite
Terminated·JJawaharlal Institute of Postgraduate Medical Education & Research·Phase 4·NCT02570347·66 enrolled
Effectiveness of Saccharomyces Boulardii in the Prevention of Antibiotic-Associated Diarrhea Among Children Receiving Co-amoxiclav for Upper Respiratory Tract Infection: A Randomized Control Trial
Not yet recruiting·UUniversity of Child Health Sciences and Children's Hospital, Lahore·Preclinical·NCT07785206·88 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Co-amoxiclav. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- IImperial College London